Inflammatory bowel disease and the gut microbiota

Nan Wu, Cassandra Mah, Sabrina Koentgen, Leo Yu Zhang, Michael Grimm, Emad El‐Omar, Georgina L. HoldProceedings of The Nutrition Society 2021 · DOI

Abstract

Inflammatory bowel disease (IBD) is a group of immune-mediated disorders characterised by a chronic, relapsing-remitting inflammation predominantly affecting the gastrointestinal tract. IBD is incurable, affecting people in their most productive years. IBD is historically seen as a disease of Westernised nations although in recent times other countries have seen an exponential rise in cases. Although the exact pathogenesis remains unclear, evidence suggests that microbiota changes play a critical role in IBD pathogenesis. Over the past two decades, IBD has become one of the most studied human conditions linked to the gut microbiota. However, deciphering the intricate link between the gut microbiota and therapeutic efficacy remains elusive. This review summarises the current evidence relating to the gut microbiota and its involvement in IBD pathogenesis as well as the impact of IBD treatments including pharmaceutical-, nutraceutical- and microbial-focused regimens on the gut microbiota.

Introduction: The "Perfect Storm" of IBD

Inflammatory Bowel Disease (IBD) encompasses chronic, incurable inflammatory conditions of the gastrointestinal tract, most notably Crohn’s disease (CD) and ulcerative colitis (UC). While once considered a disease of the Western world, its incidence is now rising globally. The current consensus on IBD pathogenesis points to a "perfect storm" involving genetic susceptibility, environmental triggers, and an aberrant immune response to the gut microbiota.

Figure 1: Pathological features of Crohn's Disease (CD), including strictures and patchy involvement.

Distinguishing between the two primary forms of IBD is crucial for management. Crohn’s disease is often characterized by "skip lesions" or patchy involvement throughout the GI tract and can lead to complications like strictures (Figure 1). In contrast, Ulcerative Colitis typically presents with continuous inflammation starting from the rectum and extending proximally (Figure 2).

Figure 2: Continuous inflammation characteristic of Ulcerative Colitis (UC).

The Microbiome in IBD: Volatility vs. Stability

A hallmark of the IBD gut is "microbial volatility." Unlike the relatively stable microbial communities found in healthy individuals, the IBD microbiome undergoes dramatic shifts in composition over time. Research using longitudinal cohorts, such as the Swiss IBD Cohort, has shown that while patients' microbiomes may occasionally drift toward a "healthy" state, they rarely maintain that stability, oscillating instead between various dysbiotic profiles.

Impact of Pharmaceutical and Dietary Interventions

Current IBD treatments, while primarily targeting the immune system, significantly reshape the microbial landscape.

Biologics and Diversity

Anti-TNF-α inhibitors, such as infliximab, are cornerstones of IBD therapy. Successful treatment with these biologics often results in a shift toward a healthier microbial profile within six weeks, characterized by increased alpha-diversity and an abundance of short-chain fatty acid (SCFA)-producing bacteria. Conversely, a reduction in specific beneficial microbes like Faecalibacterium prausnitzii has been identified as a predictive marker for relapse after treatment cessation.

The EEN Paradox and CD-TREAT

Exclusive Enteral Nutrition (EEN)—a liquid-only diet—is a primary therapy for pediatric CD. Interestingly, EEN actually decreases microbial diversity during successful induction of remission, suggesting that clinical improvement does not always require an immediate increase in richness. To address the poor compliance associated with liquid diets, the CD-TREAT study introduced a solid-food-based alternative that mimics EEN's effects. CD-TREAT achieved an 80% clinical improvement rate in children, demonstrating that dietary interventions can effectively modulate the microbiome to achieve therapeutic goals.

Microbial-Focused Therapies: The FMT Landscape

Fecal Microbiota Transplantation (FMT) has emerged as a promising, albeit complex, therapy. Clinical trials have demonstrated significant efficacy for FMT in inducing remission in Ulcerative Colitis, with success rates of 24–27% compared to 5–8% for placebos. However, FMT has been largely ineffective for Crohn’s Disease, highlighting the distinct biological drivers of the two conditions. A key finding in successful UC trials is the "super-donor" phenomenon, where the stool from specific donors leads to disproportionately better outcomes, suggesting that the specific ecological composition of the donor microbiota is a critical determinant of success.

Conclusion: Toward Personalized Microbiome Medicine

The shift from searching for a single causative pathogen to understanding IBD as an ecosystem-level failure has opened new therapeutic avenues. The future of IBD management lies in personalized medicine, where baseline microbial signatures are used as biomarkers to predict response to biologics, diets, or microbial transplants. While challenges remain in standardizing methodologies and establishing long-term stability of microbial shifts, the integration of microbiome data into clinical practice promises a more targeted and effective approach to this complex disease.

Summary updated

Abstract

Inflammatory bowel disease (IBD) is a group of immune-mediated disorders characterised by a chronic, relapsing-remitting inflammation predominantly affecting the gastrointestinal tract. IBD is incurable, affecting people in their most productive years. IBD is historically seen as a disease of Westernised nations although in recent times other countries have seen an exponential rise in cases. Although the exact pathogenesis remains unclear, evidence suggests that microbiota changes play a critical role in IBD pathogenesis. Over the past two decades, IBD has become one of the most studied human conditions linked to the gut microbiota. However, deciphering the intricate link between the gut microbiota and therapeutic efficacy remains elusive. This review will summarise the current evidence relating to the gut microbiota and its involvement in IBD pathogenesis as well as the impact of IBD treatments including pharmaceutical-, nutraceutical- and microbial-focused regimens on the gut microbiota.
BibTeX
@inproceedings{wu2021inflammatory,
  author = {Nan Wu and Cassandra Mah and Sabrina Koentgen and Leo Yu Zhang and Michael Grimm and Emad El‐Omar and Georgina L. Hold},
  title = {{Inflammatory bowel disease and the gut microbiota}},
  booktitle = {Proceedings of The Nutrition Society},
  year = {2021},
  doi = {10.1017/s002966512100197x},
}
Figure